ROCKVILLE, MD and SHENZHEN, CHINA, November 10, 2026 – HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today announced that it will present preclinical findings on HTD1801 in obesity management on November 15, 2026, at ObesityWeek 2026, in Washington, D.C., US.
HTD1801 is positioned to address multiple metabolic disorders by acting on the AMPK–NLRP3 axis to target both metabolic dysregulation and inflammation. The findings highlight the potential of HTD1801 to enhance weight loss in combination with GLP-1RAs and mitigate body weight rebound following GLP-1RA withdrawal, while also delivering broader metabolic benefits.
Presentation Title: HTD1801 Add-On to Incretin-Based Agents Amplifies Weight Loss, Preserves Lean Mass and Curbs Rebound
Presentation Number: Poster-387
Date and Time: November 15, 2026, 2:30 PM–3:30 PM EST
Format: Poster Presentation
Presenter: Dr. Liping Liu, Founder, Chairperson, and CEO of HighTide Therapeutics
About HTD1801
HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts its biological activity through the AMPK–NLRP3 axis, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across CKM diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
For more information, please visit www.hightidetx.com, Contact: pr@hightidetx.com